IVD Companion Diagnostic Co-Development: How to Structure a Pharma-Diagnostics Partnership That Works
If you work at the intersection of oncology drug development and in vitro diagnostics, you have probably seen a companion diagnostic partnership go sideways.
The science is rarely the problem. The structure is.
Successful co-development partnerships require aligned governance, synchronized regulatory strategy, clear IP ownership, and reimbursement planning built from the beginning rather than added later.
This guide explores how pharma and diagnostics companies can structure companion diagnostic partnerships that survive Phase III, regulatory review, and commercial launch.
Key takeaways
- A companion diagnostic is a regulatory co-applicant, not a service vendor.
- Retrofitting CDx strategy after Phase II is costly and avoidable.
- Drug and IVD regulatory timelines must stay synchronized throughout development.
- Reimbursement strategy must be integrated during development, not after approval.
What companion diagnostics actually require from your partnership
A companion diagnostic (CDx) is an in vitro diagnostic device essential to the safe and effective use of a specific therapeutic.
Operationally, this means the drug and the diagnostic become co-dependent assets. One cannot succeed commercially or regulatorily without the other.
Your IVD partner is not simply a testing vendor. They are a regulatory co-developer with their own submission obligations, quality systems, commercialization responsibilities, and long-term platform commitments.
The real reasons CDx programs break down
Retrofitting the CDx after Phase II
Building a companion diagnostic after late-stage clinical development often creates major validation and regulatory problems.
Archived samples collected without CDx-grade protocols rarely meet the analytical standards required for regulatory approval.
Ambiguous IP ownership
Assay design, biomarker data, software workflows, and validation evidence all create intellectual property considerations.
Without clear ownership definitions, disputes emerge during critical development phases.
Regulatory timeline desynchronization
Drug and diagnostic timelines must evolve together. When one side accelerates or delays without synchronized planning, regulatory risk increases significantly.
Reimbursement as an afterthought
FDA approval alone does not guarantee payer reimbursement or market access.
Health economics evidence and reimbursement planning must begin during development.
What the biomarker landscape looks like right now
The immuno-oncology biomarker ecosystem is becoming more complex and more multi-dimensional.
Single-marker approaches such as PD-L1 are being replaced by multi-omic strategies combining:
- Genomic data
- Transcriptomic signatures
- Proteomic analysis
- Spatial biology workflows
- Tumor microenvironment profiling
The major challenge is translating this scientific complexity into standardized, reproducible, regulatory-grade companion diagnostics.
What a functional co-development structure looks like
| Structural element | Purpose |
| Joint Steering Committee | Coordinates timelines, governance, and strategic decisions |
| IP ownership clauses | Defines ownership across assays, data, software, and validation assets |
| Regulatory co-planning | Keeps FDA and global submission pathways synchronized |
| Reimbursement co-strategy | Builds payer evidence during development |
| Platform development pathway | Determines long-term IVD commercialization model |
Functional partnerships align governance, scientific development, regulatory execution, and commercialization planning from the earliest stages.
Why Boston is where this conversation is happening
The Boston-Cambridge biotech corridor remains one of the most concentrated precision medicine ecosystems in the world.
Major pharma companies, diagnostics developers, academic medical centers, and translational research groups operate within the same innovation environment.
For CDx partnerships, this concentration accelerates networking, collaboration, and decision-making in ways few other locations can replicate.
What happened at ImmunoMark Summit London 2026
The London 2026 edition of ImmunoMark Summit brought together more than 400 attendees across two parallel scientific tracks.
Sessions covered:
- CAR-T and multi-antigen targeting
- AI-driven biomarker standardization
- Extracellular vesicle profiling
- CDx commercialization strategies
- Biomarkers as market-makers in oncology
Sponsor and attendee feedback consistently highlighted the senior audience quality and structured networking environment.
What Boston 2026 is built to deliver
ImmunoMark Summit Boston 2026 is designed to connect scientific discovery with clinical, translational, and commercial oncology applications.
Stream 1: Immuno-Oncology
- Next-generation IO therapies
- CAR-T and NK cell therapies
- Bispecifics and ADCs
- Tumor microenvironment biology
- Resistance mechanisms
Stream 2: Biomarkers & CDx
- Biomarker-first drug development
- Liquid biopsy and MRD
- Spatial biology and multi-omics
- AI for biomarker discovery
- CDx regulatory pathways and commercialization
The summit also includes structured 1:1 meetings, networking receptions, and curated discussions with senior pharma and diagnostics leaders.
Who should be there
The event is designed for professionals across the full precision medicine and CDx ecosystem:
- Pharma and biotech executives
- Companion diagnostic developers
- Translational medicine leaders
- Regulatory specialists
- Clinical trial investigators
- Biomarker scientists and platform developers
The conversation you need to be part of
Most CDx partnership failures are not caused by weak science.
They fail because of unclear governance, poor regulatory synchronization, reimbursement gaps, and partnership structures that were never designed for long-term co-development.
ImmunoMark Summit Boston 2026 is where those conversations are happening at the highest level.
#PrecisionMedicine
#ImmunoOncology
#Biomarkers
#CDxDevelopment
